1[1]CIBIS-Ⅱ Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study Ⅱ (CIBIS Ⅱ): a randomized trial. Lancet, 1999,353: 9-13.
2[2]MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet, 1999, 353:2001-2007.
3[3]Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med, 2001,344:1651-1658.
4[5]Packer M, Cohn JN, Abraham WT, et al. Consensus recommendations for management of chronic heart failure. Am J Cardiol, 1999, 83:1A-38A.
5[6]Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. Guidelines for the diagnosis and treartment of chronic heart failure. Eur Heart J,2001, 22:1527-1560.
6[7]Bristow MR, Gilbert EM, Abraham WT, et al. Carvediol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation,1996, 94:2807-2816.
7[8]Wikstrand J, Hjalmarson A, Waagstein F, et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure. Analysis of the experience in Metoprolol CR/XL Randomized International Trial in Chronic Heart Failure (MERIT-HF). J Am Coll Cardiol, 2002, 40:491-498.
8[9]Simon T, Mary-Krause M, Furck-Brentano C, et al. Bisoprolol dose-response relationship in patients with congestive heart failure: a subgpoup analysis in the cardiac insufficiency bisoprolol study (CIBIS Ⅱ ). Eur Heart J, 2003, 24:552-559.
9[10]Poole-Wilson PA, Cleland JGF, Lenarda AD, et al. Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET. Eur J Heart Fail,2002, 4:321-329.
10[11]Poole-Wilson PA, Swedberg K, Cleland JGF, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. Lancet, 2003, 362:7-13.
